A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Exclusion Criteria

• •1. Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1
• •2. Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1
• •3. Orthostatic hypotension with symptoms within 3 months prior to visit 1
• •4. Secondary hypertensive patient or suspected to be
• •5. Clinically significant hematological finding
• •6. Severe heart disease or severe neurovascular disease
• •7. Moderate or malignant retinopathy
• •8. Uncontrolled diabetes mellitus(HbA1c \> 9%) or type I diabetes mellitus
• •9. Active gout or hyperuricemia (uric acid ≥ 9mg/dL)
• •10. Severe renal diseases (eGFR \< 30mL/min/1.73m2)
• •11. Severe or active hepatopathy (AST or ALT ≥ 3 times of normal range)
• •12. Hypokalemia or Hyperkalemia (K \< 3.5mmol/L or K ≥ 5.5mmol/L)
• •13. Hyponatremia or Hypernatremia (Na \< 135mmol/L or Na ≥ 155mmol/L)
• •14. Hypercalcemia (Ca \> 12.5mg/dL)
• •15. History of malignancy tumor
• •16. History of autoimmune disease
• •17. History of alcohol or drug abuse
• •18. Positive to pregnancy test, nursing mother, intention on pregnancy
• •19. Considered by investigator as not appropriate to participate in the clinical study with other reason